For Patients

Life threatening abnormal heart rhythms may cause sudden cardiac death. At present, the individual patient’s risk to experience such dangerous arrhythmias is to a large extent estimated on the basis of cardiac pump function and the history of occurrence of dangerous arrhythmias. If an increased risk for dangerous arrhythmias is established, an automated ICD device is often recommend to patients to prevent dangerous arrhythmias and sudden cardiac arrest by cardiac electroconversion therapy (also known as defibrillation) as summarized in the following figure:

110217 ekg kopie

The EUTrigTreat clinical trial investigates the dangerous heart rhythm disturbances (arrhythmias that need to be treated with ICD device therapy) through novel diagnostic strategies to assess real arrhythmia risk in patients. In addition, the relationship of arrhythmias with common arrhythmia risk-modifiers including diabetes or kidney dysfunction, and genetic factors is investigated. The EUTrigTreat clinical trial aims to improve the treatment and prevention of dangerous heart rhythm disturbances through improved identification of patients with increased arrhythmia risk, and is supported by the European Commission to answer this important question.



Patients who would like to enroll in the EUTrigTreat clinical trial receive comprehensive clinical arrhythmia risk assessment including diagnostic cardiac electrophysiology tests and metabolic and genetic blood tests. The clinical trial will improve the prediction of the individual patient’s risk for dangerous heart rhythm disturbances. This is an important question because many patients who receive ICD device implantation in agreement with current treatment guidelines may never experience a lifesaving treatment by the device, and therefore improved arrhythmia risk prediction will be of immediate benefit for many patients. A follow-up patient visit in the Goettingen ICD ambulance is shown in the picture.

The EUTrigTreat study is conducted with the help of patients voluntarily participating at five European university hospitals (Athens, Glasgow, Goettingen, Leuven and Utrecht). After completion of comprehensive enrolment diagnostic tests (ECG, exercise test, 24-hour Holter monitoring, echocardiography, electrophysiology) follow-up is performed every 6 months until study completion in 2014.

Rationale, objectives, and design of the EUTrigTreat clinical study

For additional information, please contact Mrs. Genzel or Mrs. Regner from the Goettingen clinical trial office under phone number +49-(0)551-39-10266. The clinical trial is directed by Prof. Dr. M. Zabel, Dept. of Cardiology & Pulmonology at the University Medical Center Goettingen.